When Deepinder Goyal recently appeared on a popular podcast wearing a small metallic device clipped to his temple, it triggered a wave of curiosity across social media. Viewers were quick to notice the unusual accessory, and within hours, questions began circulating: What is that device? What does it do? Is it safe? And when can people buy it?
The device is called Temple—an experimental brain-monitoring wearable currently under trial. While it is not yet a commercial product, its public appearance has sparked widespread discussion about the future of health wearables and how far personal health tracking can go beyond steps, sleep, and heart rate.
This article breaks down everything that is currently known about Temple, separating fact from speculation.
What Exactly Is the Temple Device?
Temple is a prototype wearable designed to monitor cerebral blood flow in real time. Unlike mainstream wearables that focus on cardiovascular or activity metrics, Temple aims to track how blood flows through the brain—one of the most critical but least continuously measured aspects of human health.
The device is worn near the temple region of the head and is designed for long-duration use. According to publicly shared information, it is lightweight, non-invasive, and intended to work passively in the background while collecting data.
Importantly, Temple is not a consumer gadget yet. It remains an experimental research device and is currently being used by a very limited group, including Goyal himself.
Why Is Deepinder Goyal Building This?
Temple is being developed under Goyal’s personal research initiative, separate from Zomato or its parent company. His interest stems from a broader exploration into ageing, cognition, and long-term brain health.
At the core of this effort is what Goyal has described as the Gravity Ageing Hypothesis—the idea that gravity may, over decades, subtly affect blood circulation to the brain and contribute to cognitive decline. While this hypothesis is unconventional and not yet scientifically established, it has motivated the creation of a device capable of collecting continuous, real-world brain-related data over long periods.
To support this work, Goyal has reportedly committed significant personal capital, positioning Temple as a curiosity-driven research effort rather than a startup chasing rapid commercialisation.
How Does Temple Work—In Simple Terms?
Temple is designed to continuously capture signals related to cerebral blood flow. In theory, fluctuations in blood flow can offer insights into:
- Mental fatigue and cognitive load
- Stress and recovery patterns
- Focus and alertness
- Age-related neurological changes
Traditional brain-health measurements are usually conducted in hospitals using bulky, expensive equipment and only provide snapshots in time. Temple’s ambition is different: continuous monitoring in real-world conditions.
However, it is important to emphasise that how accurately Temple captures and interprets these signals—and what conclusions can reliably be drawn from them—has not yet been validated through published clinical studies.
Is Temple Medically Approved or Doctor-Recommended?
As of now, no.
Temple is not a medically certified device, nor has it received regulatory approval as a diagnostic or therapeutic tool. There are no publicly available peer-reviewed studies validating its accuracy or clinical usefulness.
Medical professionals have expressed mixed reactions. While many agree that cerebral blood flow is an important health marker, they also caution that measuring it reliably outside clinical settings is extremely complex. Without transparent data and validation, Temple should be viewed as an experimental research wearable, not a medical device.
Anyone considering such technology in the future should not use it as a substitute for professional medical advice or diagnosis.
When Will Temple Launch?
There is no official launch timeline. Temple is still in the prototype and testing phase. No announcements have been made regarding:
- Commercial availability
- Regulatory approvals
- Companion apps or data dashboards
- Consumer trials or beta programs
The recent podcast appearance has increased public visibility, but visibility should not be confused with readiness for market. At best, Temple may see limited pilot usage before any broader rollout—if it reaches that stage at all.
Expected Price: What Could It Cost If Launched?
There is no confirmed pricing, but informed estimates can be made based on comparable advanced health wearables.
If Temple ever reaches consumers, it would likely sit in the premium segment, potentially costing anywhere between ₹25,000 to ₹50,000 or more, depending on hardware sophistication, software support, and regulatory requirements.
That said, pricing remains purely speculative until an official announcement is made.
Who Might Consider Buying Temple—And Who Should Not?
If Temple does eventually become available, it may appeal to:
- Health and longevity enthusiasts
- Biohackers and quantified-self users
- Researchers studying cognition and ageing
- High-performance professionals interested in mental optimisation
However, it would not be suitable for:
- Individuals seeking medical diagnosis or treatment
- Patients with neurological conditions
- Users expecting clear, doctor-backed health recommendations
Until proven otherwise, Temple’s data should be seen as exploratory and informational, not actionable medical guidance.
Why Temple Matters, Even If It Never Launches
Regardless of whether Temple becomes a consumer product, it represents a broader shift in health technology—from surface-level metrics to deeper physiological monitoring. The device highlights growing interest in understanding brain health outside hospital walls and over long time horizons.
Temple has also reignited debate about where innovation ends and pseudoscience begins—a tension that is inevitable when ambitious ideas push into poorly understood territory.
The Bottom Line
Temple is not a gadget you can buy, not a medically approved device, and not a proven solution for brain health—at least not yet.
What it is, however, is a bold experiment led by Deepinder Goyal, aimed at exploring uncharted territory in continuous brain monitoring. Its recent public appearance has amplified curiosity, but for now, Temple remains a research-stage prototype with more questions than answers.
For consumers, the right approach is cautious interest—not blind optimism. The science will need to speak before Temple can move from conversation to credibility.
